Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Stock Liabilities (2023 - 2024)

Contineum Therapeutics (CTNM) has 2 years of Preferred Stock Liabilities data on record, last reported at $192.6 million in Q1 2024.

  • For Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $192.6 million; the TTM value through Mar 2024 reached $192.6 million, changed N/A, while the annual FY2023 figure was $192.6 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $192.6 million in Q1 2024 per CTNM's latest filing, roughly flat from $192.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $192.6 million in Q4 2023 and bottomed at $192.6 million in Q4 2023.